Crinetics Pharmaceuticals (CRNX) AI Stock Analysis

• Market Cap: $4.00B
• Dividend Yield: N/A
• Average Volume (3M): 1.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: N/A
• EPS Growth: -9.10%
• Country: US
• Employees: 437
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.38
• Shares Outstanding: 94,175,995
• 10 Day Avg. Volume: 1,225,875
• 30 Day Avg. Volume: 1,780,007
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $78.33
• Price Target Upside: 80.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $44.00 ▲(1.17% Upside)

Crinetics Pharmaceuticals shows a promising technical outlook with strong upward momentum, but financial performance remains a concern due to persistent losses and cash flow issues. The positive sentiment from the earnings call highlights potential future growth, but immediate valuation challenges persist due to negative earnings.

Positive Factors

FDA Approval

The FDA approval of PALSONIFY for acromegaly marks a significant milestone, potentially enhancing revenue streams and market presence as the first oral treatment option, strengthening Crinetics' competitive position in the endocrine disorder market.

Strong Cash Position

A robust cash reserve enables Crinetics to fund operations into 2029, providing financial stability and flexibility to invest in R&D and commercial activities, crucial for long-term growth and resilience in the biotech sector.

Pipeline Progress

Ongoing clinical trials and pipeline expansion indicate a strong commitment to innovation, potentially leading to new product approvals and diversified revenue sources, enhancing long-term growth prospects.

Negative Factors

Operational Losses

Continued operational losses highlight challenges in achieving profitability, which could strain cash reserves and limit the ability to invest in future growth, posing risks to financial sustainability.

Increased Operating Expenses

Rising R&D and administrative expenses reflect strategic investments but may pressure margins and delay profitability, affecting financial health if not matched by revenue growth.

Challenges in Launch Uptake

Gradual market adoption of PALSONIFY due to factors like formulary placement delays could impact initial revenue generation, affecting short-term financial performance and market penetration.

Crinetics Pharmaceuticals Business Overview & Revenue Model

Company Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

How the Company Makes Money

Crinetics Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company may earn revenue from licensing agreements with larger pharmaceutical partners, who may fund the development and marketing of its products in exchange for a share of future sales or milestone payments. Additionally, Crinetics could receive grants or funding from governmental and non-governmental organizations for research purposes. Furthermore, successful clinical trials leading to regulatory approvals can increase the company's valuation and attract investment, thus contributing to its overall financial health.

Crinetics Pharmaceuticals Financial Statement Overview

Summary

Crinetics Pharmaceuticals faces significant financial challenges, with persistent operational losses and cash flow issues. While recent financing has strengthened the cash position, the company's ability to generate sustainable revenue and profit remains unproven. The balance sheet shows improvement, but historical financial instability highlights the need for caution.

Income Statement

Crinetics Pharmaceuticals has experienced fluctuating revenue with a decline from 2022 to 2023, followed by a sharp drop in 2024. The gross profit margin is consistently high, but net losses persist, indicating ongoing profitability challenges. Negative EBIT and EBITDA margins reflect operational inefficiencies.

Balance Sheet

The company shows a strong equity position with substantial cash reserves and minimal debt. However, negative stockholders' equity in earlier years indicates past financial distress. Current liabilities are relatively low, but the debt-to-equity ratio is a concern due to historical negative equity.

Cash Flow

Operating cash flow remains negative, highlighting potential liquidity challenges. Free cash flow is also consistently negative, though recent financing activities have bolstered cash reserves. Stability in cash flow remains a concern with ongoing operational losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.39M	1.04M	4.01M	4.74M	1.08M	71.00K
Gross Profit	-149.00K	1.04M	4.01M	3.35M	-184.00K	-56.93M
EBITDA	-420.58M	-338.85M	-221.51M	-166.90M	-106.78M	-72.59M
Net Income	-369.83M	-298.41M	-214.53M	-163.92M	-107.64M	-72.86M
Balance Sheet
Total Assets	1.29B	1.43B	635.35M	352.18M	351.01M	183.44M
Cash, Cash Equivalents and Short-Term Investments	1.20B	1.35B	558.55M	334.43M	333.71M	170.88M
Total Debt	49.94M	51.72M	51.73M	3.08M	3.07M	4.01M
Total Liabilities	118.05M	109.79M	96.25M	35.85M	19.07M	14.53M
Stockholders Equity	1.17B	1.32B	539.11M	316.33M	331.94M	168.92M
Cash Flow
Free Cash Flow	-307.80M	-229.81M	-171.00M	-116.86M	-89.02M	-62.21M
Operating Cash Flow	-301.80M	-225.97M	-166.31M	-115.20M	-88.59M	-62.03M
Investing Cash Flow	-569.49M	-574.82M	-200.41M	-173.98M	-56.48M	217.00K
Financing Cash Flow	622.86M	1.01B	388.94M	121.96M	252.68M	114.57M

Crinetics Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.49
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Positive. The current price of 43.49 is above the 20-day moving average (MA) of 42.78, above the 50-day MA of 39.42, and above the 200-day MA of 34.00, indicating a bullish trend. The MACD of 0.89 indicates Positive momentum. The RSI at 56.78 is Neutral, neither overbought nor oversold. The STOCH value of 58.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRNX.

Crinetics Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	64 Neutral	$3.73B	―	-9.46%	―	40.54%	-264.26%
AKRO	60 Neutral	$4.36B	―	-31.14%	―	―	-11.39%
KYMR	58 Neutral	$4.31B	―	-32.09%	―	-50.05%	-54.47%
CRNX	55 Neutral	$4.00B	―	-36.94%	―	―	-9.10%
APLS	52 Neutral	$2.52B	66.39	14.10%	―	42.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RARE	50 Neutral	$3.07B	―	-325.76%	―	20.63%	8.09%

Crinetics Pharmaceuticals Corporate Events

Crinetics Pharma’s Atumelnant Study: A Promising Phase 1 Update

Crinetics Pharmaceuticals Inc. is conducting a Phase 1 study titled ‘A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants.’ The study aims to evaluate the pharmacokinetics, safety, and tolerability of the drug Atumelnant when administered in single and multiple doses to healthy volunteers from Japanese and Caucasian backgrounds. This research is significant as it explores the drug’s effects across different ethnic groups, potentially paving the way for broader applications.

Crinetics Pharma’s Paltusotine Study: A Potential Game-Changer for Carcinoid Syndrome

Crinetics Pharmaceuticals is conducting a Phase 3 study titled ‘A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors.’ The study aims to assess the efficacy and safety of paltusotine, an oral treatment, in managing carcinoid syndrome, a condition associated with neuroendocrine tumors.

Crinetics Pharma’s CRN09682 Study: A Potential Breakthrough in Tumor Treatment

Crinetics Pharmaceuticals Inc. is conducting a Phase 1/2 study titled A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors. The study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of CRN09682, a drug targeting SST2-expressing tumors.

Crinetics Pharma’s Promising Extension Study on Atumelnant: A Potential Game-Changer for Adrenal Disorders

Crinetics Pharmaceuticals is conducting an extension study titled ‘An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894.’ The study aims to assess the long-term safety, tolerability, and efficacy of atumelnant (CRN04894) in treating Congenital Adrenal Hyperplasia, a significant condition affecting adrenal gland function.

Crinetics Pharma’s New Study on Atumelnant: A Potential Game-Changer for CAH Treatment

Study Overview: Crinetics Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)’. The study aims to assess the safety and efficacy of Atumelnant in treating adults with classic congenital adrenal hyperplasia (CAH) due to 21-OHD, a condition that affects adrenal gland function.

Crinetics Pharma’s Promising Study on Atumelnant for Pediatric CAH

Study Overview: Crinetics Pharmaceuticals is conducting a Phase 2/3 study titled A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension. The study aims to assess the safety, efficacy, and pharmacokinetics of Atumelnant in children with congenital adrenal hyperplasia (CAH), a condition that affects hormone production. This research is significant as it addresses a critical need for effective treatments in pediatric endocrinology.

Crinetics Pharma’s Promising Study on CRN04894 for Cushing’s Syndrome: A Potential Game-Changer?

Crinetics Pharmaceuticals is conducting a study titled ‘A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing’s Syndrome.’ This study aims to evaluate the safety, tolerability, and pharmacokinetics of CRN04894, an ACTH receptor antagonist, in treating Cushing’s Syndrome, a condition characterized by excessive cortisol production. The study’s significance lies in its potential to offer a new treatment avenue for patients with Cushing’s disease or Ectopic ACTH Syndrome.

Crinetics Pharmaceuticals Gains FDA Approval for PALSONIFY

On September 25, 2025, Crinetics Pharmaceuticals announced that the FDA approved PALSONIFYTM (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. PALSONIFY, a once-daily oral therapy, marks a significant advancement in acromegaly treatment, offering a non-invasive alternative to traditional injections. The approval is based on successful Phase 3 trials demonstrating the drug’s efficacy and safety, and it represents a pivotal milestone for Crinetics as it enhances its position as a leader in endocrine-focused pharmaceuticals. The company is also working to ensure broad access to PALSONIFY and has launched a support program, CrinetiCARE, to assist patients throughout their treatment journey.

The most recent analyst rating on (CRNX) stock is a Buy with a $143.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Crinetics Pharma’s Earnings Call: Progress Amid Challenges

Crinetics Pharmaceuticals’ recent earnings call conveyed a mixed sentiment, highlighting both robust progress and looming challenges. The company demonstrated strong execution across its business, with notable advancements in its pipeline and financial stability. However, concerns were raised regarding high operational costs, cash usage, and potential hurdles in launching PALSONIFY.

Crinetics Pharmaceuticals Reports Q2 2025 Financial Results

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. The company’s lead development candidate, PALSONIFY (paltusotine), is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors.